| AstraZeneca PLC | Precision Medicine Platforms | $294.1b | $168.19 | -0.0% | 4.4K | |
| Thermo Fisher Scientific, Inc. | Precision Medicine Platforms | $186.3b | $537.68 | 0.0% | 3 | |
| Danaher Corporation | Precision Medicine Platforms | $134.8b | $200.95 | 0.0% | 23 | |
| Vertex Pharmaceuticals Inc | Gene Therapy & Gene Editing | $126.1b | $476.45 | 0.0% | 40 | |
| Regeneron Pharmaceuticals Inc | Gene Therapy & Gene Editing | $65.4b | $660.33 | 0.0% | 695 | |
| Alnylam Pharmaceuticals, Inc. | RNA Therapeutics | $40.2b | $279.23 | 0.0% | 21 | |
| Natera, Inc. Common Stock | Genetic Testing & Diagnostics | $38.9b | $276.11 | 0.0% | 125 | |
| Waters Corp | Precision Medicine Platforms | $36.8b | $374.42 | 0.0% | N/A | |
| Illumina Inc | Genetic Testing & Diagnostics | $26.6b | $187.38 | 0.0% | 65 | |
| Insmed, Inc. | Gene Therapy & Gene Editing | $23.1b | $109.25 | 0.0% | 75 | |
| Labcorp Holdings Inc. | Genetic Testing & Diagnostics | $23.0b | $274.50 | 0.0% | 111 | |
| Guardant Health, Inc. Common Stock | Precision Medicine Platforms | $19.9b | $162.00 | 0.0% | 28 | |
| BridgeBio Pharma, Inc. Common Stock | Precision Medicine Platforms | $14.6b | $82.50 | 0.0% | 460 | |
| Ionis Pharmaceuticals, Inc. Common Stock | RNA Therapeutics | $13.1b | $54.88 | 0.0% | 676 | |
| Revvity, Inc. | Precision Medicine Platforms | $12.4b | $108.01 | -0.0% | 222 | |
| Arrowhead Research Corporation | RNA Therapeutics | $11.5b | $71.72 | 0.0% | 33 | |
| BioMarin Pharmaceuticals Inc | Gene Therapy & Gene Editing | $11.1b | $59.05 | 0.0% | N/A | |
| Bio-Techne Corp. | Precision Medicine Platforms | $11.0b | $71.48 | 0.0% | N/A | |
| Krystal Biotech, Inc. Common Stock | Gene Therapy & Gene Editing | $11.0b | $350.59 | 0.0% | N/A | |
| Tempus AI, Inc. Class A Common Stock | Precision Medicine Platforms | $10.4b | $56.77 | 0.0% | 11.0K | |
| Nuvalent, Inc. Class A Common Stock | Precision Medicine Platforms | $9.8b | $123.96 | 0.0% | N/A | |
| Kymera Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $9.4b | $116.45 | 0.0% | 431 | |
| Praxis Precision Medicines, Inc. Common Stock | Precision Medicine Platforms | $9.3b | $327.55 | 0.0% | 119 | |
| QIAGEN N.V. | Genetic Testing & Diagnostics | $8.1b | $41.51 | 0.0% | 140 | |
| Lantheus Holdings, Inc | Precision Medicine Platforms | $7.2b | $104.30 | 0.0% | 496 | |
| Twist Bioscience Corporation Common Stock | Precision Medicine Platforms | $6.4b | $92.74 | 0.0% | 57 | |
| BillionToOne, Inc. Class A Common Stock | Genetic Testing & Diagnostics | $5.5b | $137.65 | 0.0% | 5 | |
| CRISPR Therapeutics AG | Gene Therapy & Gene Editing | $5.4b | $51.45 | 0.0% | 884 | |
| Caris Life Sciences, Inc. Common Stock | Precision Medicine Platforms | $5.0b | $17.62 | 0.0% | N/A | |
| 10x Genomics, Inc. Class A Common Stock | Genetic Testing & Diagnostics | $4.9b | $45.75 | 0.0% | 129 | |
| Veracyte, Inc. | Genetic Testing & Diagnostics | $4.7b | $60.01 | 0.0% | 404 | |
| Amicus Therapeutics, Inc | Gene Therapy & Gene Editing | $4.5b | $14.49 | +0.0% | 3.5M | |
| Dyne Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $3.7b | $23.93 | 0.0% | 108 | |
| IDEAYA Biosciences, Inc. Common Stock | Precision Medicine Platforms | $3.6b | $36.25 | 0.0% | N/A | |
| Beam Therapeutics Inc. Common Stock | Gene Therapy & Gene Editing | $3.5b | $31.02 | 0.0% | 331 | |
| Adaptive Biotechnologies Corporation Common Stock | Precision Medicine Platforms | $3.4b | $22.93 | 0.0% | 1.0K | |
| uniQure N.V. | Gene Therapy & Gene Editing | $3.2b | $40.28 | 0.0% | 3.1K | |
| Intellia Therapeutics, Inc | Gene Therapy & Gene Editing | $2.4b | $12.96 | 0.0% | 8.7K | |
| Vericel Corporation | Gene Therapy & Gene Editing | $2.3b | $47.42 | 0.0% | 111 | |
| GeneDx Holdings Corp. Class A Common Stock | Precision Medicine PlatformsGenetic Testing & Diagnostics | $2.0b | $64.83 | 0.0% | 8 | |
| Precigen, Inc. Common Stock | Gene Therapy & Gene Editing | $2.0b | $5.09 | 0.0% | N/A | |
| Taysha Gene Therapies, Inc. Common Stock | Gene Therapy & Gene Editing | $2.0b | $6.15 | 0.0% | 9 | |
| NeoGenomics, Inc. | Genetic Testing & Diagnostics | $1.9b | $14.48 | 0.0% | N/A | |
| Sarepta Therapeutics,, Inc. Common Stock | Gene Therapy & Gene Editing | $1.9b | $17.52 | 0.0% | 120 | |
| Maze Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $1.7b | $30.04 | 0.0% | N/A | |
| CareDx, Inc. | Genetic Testing & DiagnosticsPrecision Medicine Platforms | $1.5b | $29.75 | 0.0% | 971 | |
| Personalis, Inc. Common Stock | Genetic Testing & Diagnostics | $1.4b | $15.88 | 0.0% | 413 | |
| BioLife Solutions Inc. | Gene Therapy & Gene Editing | $1.4b | $28.92 | 0.0% | 214 | |
| MeiraGTx Holdings plc Ordinary Shares | Gene Therapy & Gene Editing | $1.3b | $12.57 | 0.0% | N/A | |
| Azenta, Inc. | Genetic Testing & Diagnostics | $1.2b | $26.71 | 0.0% | 2 |